Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2021 Aug 13;35(6):1085–1101. doi: 10.1016/j.hoc.2021.07.004

Table 2.

Currently approved VWF concentrates in the United States

Product Type VWF RCo:VWF Ag ratio VWF RCo:FVIII ratio Mean half life (hours)
Alphanate Plasma derived 0.47 ± 0.1 1.33 ± 0.26 17.9 ± 9.6
Humate Plasma derived 0.59 ± 0.1 2.45 ± 0.3 ~12.2
Vonvendi Recombinant 1.16 ± 0.25 No FVIII 21.9 ± 8.36
Wilate Plasma derived NA 1.0 19.6 ± 6.9